(54) found that administering GIPR antagonist to healthy humans reduced postprandial insulin secretion and increased glucose excursions more than administering GLP-1R antagonist (GLP-1RA), indicating that endogenous GIP may play a more significant role in stimulating insulin secretion and reducing postprandial plasma glucose excursions compared to endogenous GLP-1
GLP-1, or Glucagon-like peptide-1, is a hormone that your small intestine produces
Ozempic contains semaglutide and is approved for type 2 diabetes, while Wegovy contains semaglutide and is approved for chronic weight management
Huang, G., Zhang, Y., Zhang, Y
Staying on a lower tolerable dose beats quitting entirely
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases